Study Reveals Link Between Diabetes and Sleep Disorders

COMISA has gained recognition as a critical issue in sleep medicine. It is estimated that obstructive sleep apnea affects 9 to 38 percent of the general population, while insomnia is similarly widespread. Alarmingly, there is considerable overlap between these conditions: approximately 30 to 50 percent of sleep apnea patients also report chronic insomnia symptoms, and 30 to 40 percent of insomnia patients show objective signs of sleep-disordered breathing. Previous studies have linked COMISA to higher risks of cardiovascular disease and diabetes, suggesting the combination poses greater risks than either disorder alone.

For this study, researchers utilized the TURKAPNE, a prospective national registry that includes adults aged 18 to 80 with suspected sleep apnea. The analysis included 12,715 patients who underwent polysomnography, the gold-standard sleep test. Obstructive sleep apnea was defined by an apnea-hypopnea index of at least five events per hour, while insomnia was identified through standardized questions regarding sleep initiation and maintenance difficulties. Diabetes was determined based on self-reported physician diagnosis or antidiabetic medication use.

The findings revealed that 25.7 percent of participants had COMISA. Among those with COMISA, diabetes was more prevalent (22.8 percent) compared to those without the disorder (15.4 percent). Conversely, roughly one-third of diabetic patients (33.9 percent) met the criteria for COMISA, compared to 24.1 percent of non-diabetics. After adjusting for demographic and health factors, diabetes was independently associated with COMISA, suggesting a notable population-level impact.

Polysomnographic data showed that diabetic patients experienced shorter sleep durations and greater sleep disturbances compared to non-diabetics. Their total sleep time averaged 353.5 minutes, while non-diabetics averaged 369.0 minutes. Diabetic individuals spent more time awake after initially falling asleep and demonstrated higher apnea-hypopnea and oxygen desaturation indices.

The interplay between diabetes and COMISA appears to be bidirectional. Sleep apnea can exacerbate metabolic dysfunction through factors like intermittent hypoxia and inflammation, which negatively impact insulin sensitivity. Similarly, insomnia may contribute to metabolic issues through chronic arousal and cortisol elevation, leading to a self-perpetuating cycle of worsening sleep and metabolic health.

In particular, the data indicated that diabetic patients with COMISA were more likely to struggle with maintaining sleep, pointing to potential nocturnal complications related to blood sugar management. The study also highlighted a higher prevalence of female participants among diabetic patients with COMISA, emphasizing the need for clinicians to pay attention to atypical presentations of sleep disorders in women.

The authors suggest that diabetes patients should be systematically screened for both insomnia and sleep-disordered breathing, advocating for integrated treatment options such as positive airway pressure therapy coupled with cognitive behavioral therapy for insomnia. While more research is needed to determine whether addressing COMISA can improve glycemic control and reduce health risks, the findings underscore the importance of recognizing these interrelated health issues.

The study has limitations, including reliance on self-reported data for diabetes diagnosis and potential generalizability issues due to the exclusively Turkish cohort. However, the significant statistical findings prompt a reconsideration of how diabetes and sleep disorders are addressed in clinical practice.